Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Patient-Derived Antibody Ameliorates Disease Severity in a Relapsing Remitting Murine Model of Multiple Sclerosis.

Annals of neurology·2026
Same author

Clinical and radiological outcomes of directed treatment transitions from Gilenya<sup>®</sup> to generic fingolimod.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Inebilizumab: Pediatric Case Series in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder.

Pediatric neurology·2025
Same author

First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial.

EBioMedicine·2025
Same author

Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.

Journal of neurology·2025
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025
Same journal

Isolated Cranial Tremors: A Reappraisal.

Seminars in neurology·2026
Same journal

Dystonia and Tremor.

Seminars in neurology·2026
Same journal

Pendular nystagmus and oculopalatal tremor.

Seminars in neurology·2026
Same journal

Sanjay Pandey, MBBS, MD, DNB, DM, FIAN, and Aasef Shaikh, MD, PhD.

Seminars in neurology·2026
Same journal

Tremor.

Seminars in neurology·2026
Same journal

Carotid Disease.

Seminars in neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Pearls: multiple sclerosis.

Elliot M Frohman1, Benjamin M Greenberg

  • 1Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. elliot.frohman@utsouthwestern.edu

Seminars in Neurology
|February 4, 2010
PubMed
Summary
This summary is machine-generated.

This review highlights key diagnostic challenges and management strategies for relapsing-remitting multiple sclerosis (RRMS). It emphasizes accurate diagnosis, differential considerations, and current therapeutic options for MS patients.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) impacts over 500,000 Americans, frequently appearing in neurology referrals.
  • Accurate diagnosis of MS requires understanding nuanced criteria and potential mimics.

Purpose of the Study:

  • To summarize diagnostic pearls and pitfalls in evaluating patients for multiple sclerosis.
  • To outline management strategies and available disease-modifying therapies for relapsing-remitting MS.

Main Methods:

  • Review of established diagnostic criteria for multiple sclerosis.
  • Analysis of differential diagnoses and conditions mimicking MS.
  • Summary of current therapeutic interventions and treatment algorithms for MS.

Main Results:

  • Diagnostic accuracy in MS relies on careful application of criteria and awareness of false-positive conditions.
  • Effective management involves understanding patient symptoms and available disease-modifying therapies.
  • Recognizing MS mimics prevents misdiagnosis and unnecessary treatments.

Conclusions:

  • A thorough understanding of diagnostic nuances and mimics is crucial for accurate MS evaluation.
  • Developing a treatment algorithm aids neurologists in managing MS patients with available therapies.
  • This review provides practical insights for the evaluation and management of relapsing-remitting multiple sclerosis.